Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2021 20:47 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its...
April 29, 2021 19:32 ET | Source: Mesoblast Limited

Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial

Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years oldIn these patients the benefit was further increased when remestemcel-L was used with dexamethasone as...
April 29, 2021 19:08 ET | Source: Mesoblast Limited

Mesoblast Corporate Update

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide...
March 30, 2021 19:54 ET | Source: Mesoblast Limited

Mesoblast Operational Highlights and Upcoming Milestones

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the...
March 29, 2021 08:00 ET | Source: Mesoblast Limited

Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip J....
March 08, 2021 20:03 ET | Source: Mesoblast Limited

Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful...
March 02, 2021 07:00 ET | Source: Mesoblast Limited

Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group

NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced today it has entered into subscription agreements for a total of US$110 million via the issue of 60...
February 17, 2021 06:00 ET | Source: Mesoblast Limited

Positive Outcomes of First Children Treated With Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-COVID-19 Published in Pediatrics

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics...
February 10, 2021 18:42 ET | Source: Mesoblast Limited

Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase...
February 10, 2021 17:35 ET | Source: Mesoblast Limited

Mesoblast Corporate Update

NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a...